ArticleRisk management and healthcare policy2020
Direct and Indirect Costs Associated with Coronary Artery (Heart) Disease in Tabriz, Iran.
Article in Risk management and healthcare policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global comparison of the economic costs of coronary heart disease: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Indirect Cost Analysis and Evaluation of Factors Affecting Indirect Costs in Patients Hospitalized with Acute Coronary Syndrome in Inpatient Wards of a Training and Research Hospital.Healthcare (Basel, Switzerland) · 2026Article
- Estimation of direct and indirect costs associated with obesity treatment interventions among adult populations in Iran.BMC health services research · 2026Article
- Article
- Why do patients with ischemic heart disease modify their lifestyle? a qualitative study : Motivations for lifestyle modification after IHD.BMC research notes · 2025Article
- Cost-of-Illness Analysis of Diabetic Foot Ulcer: A Prevalence-Based Approach in Southwest of Iran.Medical journal of the Islamic Republic of Iran · 2025Article
- Economic burden of cardiovascular diseases among elderly patients in Iran: a case from a developing country.BMC health services research · 2024Article
- Topology optimization of coronary artery stent considering structural and hemodynamic parameters.Heliyon · 2024Article
- Article
- Polypill versus medication monotherapy in the prevention of cardiovascular diseases in Iran: An economic evaluation study.Health science reports · 2024Article
- Article
- Cost-effectiveness of tax policies on promoting sustainable diets in Iran: a modeling study.Frontiers in nutrition · 2024Article
- Do patients need additional coverage for chronic ailments? Insights from hospital data.Journal of education and health promotion · 2024Article
- Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran.Health economics review · 2023Article
- Economic burden of breast cancer: a case of Southern Iran.Cost effectiveness and resource allocation : C/E · 2023Article
- Cardiovascular Stents: Types and Future Landscape.Cureus · 2023Review
- Economic Burden of Asthma in Northwest Iran.Iranian journal of medical sciences · 2023Article
- Change in coronary heart disease hospitalization after chronic disease management: a programme policy in China.Health policy and planning · 2023Article
- Evaluation of coronary stents: A review of types, materials, processing techniques, design, and problems.Heliyon · 2023Review
- Heart failure: a prevalence-based and model-based cost analysis.Frontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCardiovascular diseases (CVDs) are the major causes of mortalities worldwide. This study was conducted to evaluate the direct and indirect costs of coronary artery disease (CAD) in Iran. PATIENTS AND
methodsThis is a prevalence-based cost-of-illness (COI) study that estimates the direct and indirect costs of CAD. The study conducted over a six-month period from April to September in 2017. Patients were recruited from Madani hospital in Tabriz, Iran. A total of 379 patients were investigated from societal perspective. Direct costs were estimated using the bottom-up costing approach and indirect costs were estimated using the Human Capital (HC) approach. A generalized linear model of regression was used to explore the relation between total cost and socio-demographic variables. The total annual mean cost was compared to Gross Domestic Product (GDP) per capita which was reported in the form of Purchasing Power Parity (PPP) index. To deal with uncertainty, one-way sensitivity analysis was performed.
resultsTotal costs per patient in one year were estimated to be IRR 63452290.17 ($PPP 7736.19) at a 95% confidence interval (58191511.73-68713068.60), the biggest part of which is related to direct medical costs with IRR 33884019.53 per year ($PPP 4131.18) (54%). Direct non-medical costs were estimated IRR 1655936.68 ($PPP 201.89) per patient (2%) and indirect costs were estimated IRR 27912333.97 per patient ($PPP 3403.11) (44%), which 62% of indirect costs is related to patients' work absenteeism.
conclusionThis study estimates the direct (56%) and indirect (44%) costs associated with CAD. The study explores the essential drivers of the costs and provides the magnitude of the burden in terms of the share of GDP. The outcomes can be used in priority setting, in particular for cost benefit analysis, and adopting new policies regarding insurance coverage and equity issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.